German pharmaceutical and healthcare company STADA Arzneimittel AG (STDAY.PK,STDAF.PK) on Friday said that it has signed and concluded a contract for the purchase of British OTC manufacturer Thornton & Ross. The purchase price amounts to 221.12 million pounds or about 259.22 million euros. This corresponds to 193 million pounds or about 226 million euros on a so-called cash and debt-free basis, the company noted.
On August 6, STADA had announced that both the companies have agreed to negotiate exclusively on the purchase of the British OTC manufacturer.
Huddersfield-based Thornton & Ross was founded in 1922 and has several known prescription-free or OTC branded products for a wide variety of indications such as cold, pain and dermatology. The company recorded sales of 66.233 million pounds in fiscal 2012/2013, nearly 11 percent more than last year.
STADA earlier said that it would use cash on hand and existing free credit lines to finance the transaction, which is expected to contribute to net income from the time of consolidation.
STADA now said that sales will presumably be consolidated in the Group as of September 1. From that date, the transaction will also make a positive contribution to net income.
On Frankfurt's Xetra, STADA shares are currently trading at 37.47 euros, up 0.43 euros or 1.16 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.